Income Statement Bright Minds Biosciences Inc.
Equities
DRUG
CA10919W4056
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 104.31 CAD | 0.00% |
|
-2.94% | -5.54% |
| 01-09 | Bright Minds Biosciences Closes its US$175 Million Public Offering | MT |
| 01-09 | Bright Minds Biosciences Closes $175.1 Million Stock Offering | MT |
| Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
Selling General & Admin Expenses, Total | 2.31M | 2.57M | 2.21M | 1.44M | 2.53M | ||
Stock-Based Compensation (IS) | - | - | - | - | - | ||
R&D Expenses | 6.31M | 12.16M | 4.98M | 1.18M | 11.08M | ||
Other Operating Expenses, Total | 8.62M | 14.73M | 7.2M | 2.62M | 13.61M | ||
Operating Income | -8.62M | -14.73M | -7.2M | -2.62M | -13.61M | ||
Interest Expense, Total | - | - | - | -8.94K | -35.85K | ||
Interest And Investment Income | - | - | - | 30.13K | 1.52M | ||
Net Interest Expenses | - | - | - | 21.19K | 1.48M | ||
Currency Exchange Gains (Loss) | 154K | 12.15K | 14.19K | -9.31K | 189K | ||
Other Non Operating Income (Expenses) | -182K | -243K | -187K | -197K | -288K | ||
EBT, Excl. Unusual Items | -8.65M | -14.96M | -7.37M | -2.8M | -12.23M | ||
Asset Writedown | - | -2K | - | - | - | ||
EBT, Incl. Unusual Items | -8.65M | -14.96M | -7.37M | -2.8M | -12.23M | ||
Earnings From Continuing Operations | -8.65M | -14.96M | -7.37M | -2.8M | -12.23M | ||
Net Income to Company | -8.65M | -14.96M | -7.37M | -2.8M | -12.23M | ||
Net Income - (IS) | -8.65M | -14.96M | -7.37M | -2.8M | -12.23M | ||
Net Income to Common Incl Extra Items | -8.65M | -14.96M | -7.37M | -2.8M | -12.23M | ||
Net Income to Common Excl. Extra Items | -8.65M | -14.96M | -7.37M | -2.8M | -12.23M | ||
Per Share Items | |||||||
Net EPS - Basic | -4.82 | -6.06 | -1.98 | -0.65 | -1.78 | ||
Basic EPS - Continuing Operations | -4.82 | -6.06 | -1.98 | -0.65 | -1.78 | ||
Basic Weighted Average Shares Outstanding | 1.79M | 2.47M | 3.72M | 4.31M | 6.88M | ||
Net EPS - Diluted | -4.82 | -6.06 | -1.98 | -0.65 | -1.78 | ||
Diluted EPS - Continuing Operations | -4.82 | -6.06 | -1.98 | -0.65 | -1.78 | ||
Diluted Weighted Average Shares Outstanding | 1.79M | 2.47M | 3.72M | 4.31M | 6.88M | ||
Normalized Basic EPS | -3.01 | -3.79 | -1.24 | -0.41 | -1.11 | ||
Normalized Diluted EPS | -3.01 | -3.79 | -1.24 | -0.41 | -1.11 | ||
Supplemental Items | |||||||
EBITA | -8.62M | -14.73M | -7.2M | -2.62M | -13.61M | ||
EBIT | -8.62M | -14.73M | -7.2M | -2.62M | -13.61M | ||
Normalized Net Income | -5.41M | -9.35M | -4.61M | -1.75M | -7.64M | ||
Interest on Long-Term Debt | - | 2.17K | 19.75K | 8.94K | 35.85K | ||
Supplemental Operating Expense Items | |||||||
Marketing Expenses | 848K | 552K | 119K | 41.6K | 430K | ||
Selling and Marketing Expenses | 852K | 552K | 119K | 41.6K | 430K | ||
General and Administrative Expenses | 1.46M | 1.93M | 2.08M | 1.4M | 2.1M | ||
Research And Development Expense From Footnotes | 6.31M | 12.18M | 5M | 1.18M | 11.08M | ||
Net Rental Expense, Total | - | 92.37K | 15.17K | - | - | ||
Stock-Based Comp., R&D Exp. (Total) | 709K | 772K | -48.13K | 298K | 2.62M | ||
Stock-Based Comp., S&M Exp. (Total) | 3.7K | - | - | - | - | ||
Stock-Based Comp., G&A Exp. (Total) | 168K | 131K | 1.2M | 542K | 560K | ||
Stock-Based Comp., Other (Total) | - | - | - | - | - | ||
Total Stock-Based Compensation | 881K | 902K | 1.15M | 840K | 3.18M |
- Stock Market
- Equities
- DRUG Stock
- Financials Bright Minds Biosciences Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















